Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 28, 2012. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 420,000 Ordinary shares of 25 pence each.
- Purchase Date: February 28, 2012.
- Price Range: Highest price paid was 1,406.0 pence per share; lowest price paid was 1,397.5 pence per share.
- Treasury Holdings (Settled): 506,782,927 shares (9.12% of total issued share capital).
- Treasury Holdings (Including Unsettled): 508,027,927 shares (10.06% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,049,292,290 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 420,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.06% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (506,782,927 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.06% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (1,397.5 to 1,406.0 pence) against market trading data for February 28, 2012.
- Review the remaining authority for share repurchases under the mandate granted on May 5, 2011.